Investors are constantly seeking chances to make lucrative bets, and one such chance can be purchasing shares of Zydus Lifesciences. Zydus Lifesciences has seen constant growth over the past few years as the pharmaceutical business has continued to flourish. The question of whether it is a solid company to buy and what its share price objective could be in the following years has arisen as a result of this. In this piece, we’ll examine the company’s financial record in more detail, examine patterns and future expectations, and consider if Zydus Lifesciences shares would be a good long-term investment.
Zydus Lifesciences Q4: Net Profit Surges Fourfold to Rs 1,182 Crore, Revenue Up 10%
- Net Profit: Zydus Lifesciences reported a net profit of Rs 1,182 crore for Q4, a four-fold increase from Rs 296 crore in the same period last year.
- Revenue: The company’s revenue reached Rs 5,533 crore, marking a 10 percent increase from the previous year.
- EBITDA: Earnings before interest, taxes, depreciation, and amortisation (EBITDA) rose to Rs 1,629.8 crore from Rs 1,257 crore.
- EBITDA Margin: The EBITDA margin improved to 29.5 percent, up from 25 percent a year ago.
- Dividend: The board declared a final dividend of Rs 3 per equity share.
- Chronic Therapies: Chronic therapies accounted for 41.2 percent of the total India business, an increase of 360 basis points over the last three years.
- India Branded Business: The India branded business grew 8 percent year-over-year.
- FMCG Sector: The FMCG sector saw a gradual recovery, with increased demand in rural India.
- Product Launches and Approvals (US): Launched five new products and received approvals for 12 new products (including four tentative approvals) in the US during the quarter.
- Full Year Product Activity: Filed 20 ANDAs, received approvals for 46 new products (including five tentative approvals), and launched 29 new products.
- UK Expansion: Focusing on scaling up operations in the UK with differentiated and niche generics, as well as specialty products.
- US FDA Inspection: Received an inspection report from the US FDA for the injectable manufacturing site in Jarod, Gujarat, with 10 observations.
- Company Background: Founded as Cadila Laboratories in 1952, Zydus Lifesciences is now one of the top five pharmaceutical companies in India and a leading player in the US generic market.
Below are the trading platforms that you can use to purchase Zydus Lifescience Ltd shares:
➤ Zerodha
➤ Upstox
➤ Groww
➤ AngelOne
➤ ICICIDirect
| When | Maximum Price | Minimum Price |
| July 2024 | 1,171.10 | 1,018.35 |
| August 2024 | 1,217.95 | 1,059.09 |
| September 2024 | 1,266.67 | 1,101.45 |
| October 2024 | 1,241.83 | 1,079.85 |
| November 2024 | 1,291.50 | 1,123.05 |
| December 2024 | 1,304.42 | 1,134.28 |
As we step into July 2024, Zydus Lifesciences Ltd’s maximum price is expected to be ₹1,171.10, with a minimum of ₹1,018.35. In August 2024, the maximum price is projected to be ₹1,217.95, and the minimum to be ₹1,059.09. By September 2024, Zydus Lifesciences Ltd’s maximum price is anticipated to reach ₹1,266.67, with a minimum of ₹1,101.45. In October 2024, the maximum price is expected to be ₹1,241.83, and the minimum to be ₹1,079.85. Moving into November 2024, Zydus Lifesciences Ltd’s maximum price is projected to be ₹1,291.50, and the minimum to be ₹1,123.05. By December 2024, the maximum price is anticipated to reach ₹1,304.42, with a minimum of ₹1,134.28.
| When | Maximum Price | Minimum Price |
| January 2025 | 1,317.46 | 1,013.43 |
| February 2025 | 1,330.77 | 1,023.67 |
| March 2025 | 1,358.72 | 1,045.17 |
| April 2025 | 1,345.26 | 1,034.82 |
| May 2025 | 1,306.08 | 1,004.68 |
| June 2025 | 1,364.85 | 1,049.89 |
| July 2025 | 1,338.09 | 1,029.30 |
| August 2025 | 1,379.48 | 1,061.14 |
| September 2025 | 1,396.03 | 1,073.87 |
| October 2025 | 1,432.33 | 1,101.79 |
| November 2025 | 1,468.14 | 1,129.33 |
| December 2025 | 1,534.20 | 1,180.16 |
In 2025, Zydus Lifesciences Ltd is expected to see its share prices fluctuate significantly. In January, the maximum price is projected to reach ₹1,317.46, with a minimum of ₹1,013.43. By July, the maximum price is expected to be ₹1,338.09, while the minimum is projected to be ₹1,029.30. Moving towards the end of the year, December is anticipated to have the highest price of ₹1,534.20 and a minimum price of ₹1,180.16.
| When | Maximum Price | Minimum Price |
| January 2026 | 1,538.54 | 1,183.49 |
| February 2026 | 1,500.07 | 1,153.90 |
| March 2026 | 1,530.08 | 1,176.98 |
| April 2026 | 1,561.30 | 1,201.00 |
| May 2026 | 1,545.84 | 1,189.11 |
| June 2026 | 1,584.49 | 1,218.84 |
| July 2026 | 1,553.42 | 1,194.94 |
| August 2026 | 1,601.47 | 1,231.90 |
| September 2026 | 1,633.49 | 1,256.53 |
| October 2026 | 1,675.97 | 1,289.20 |
| November 2026 | 1,717.86 | 1,321.43 |
| December 2026 | 1,760.81 | 1,354.47 |
| When | Maximum Price | Minimum Price |
| January 2027 | 1,778.42 | 1,368.02 |
| February 2027 | 1,824.02 | 1,403.09 |
| March 2027 | 1,895.16 | 1,457.81 |
| April 2027 | 1,858.00 | 1,429.23 |
| May 2027 | 1,803.88 | 1,387.60 |
| June 2027 | 1,885.06 | 1,450.04 |
| July 2027 | 1,848.09 | 1,421.61 |
| August 2027 | 1,905.25 | 1,465.58 |
| September 2027 | 1,971.93 | 1,516.87 |
| October 2027 | 2,023.20 | 1,556.31 |
| November 2027 | 2,073.79 | 1,595.22 |
| December 2027 | 2,125.63 | 1,635.10 |
| When | Maximum Price | Minimum Price |
| January 2028 | 2,168.14 | 1,667.80 |
| February 2028 | 2,223.74 | 1,710.57 |
| March 2028 | 2,310.46 | 1,777.28 |
| April 2028 | 2,265.16 | 1,742.43 |
| May 2028 | 2,199.18 | 1,691.68 |
| June 2028 | 2,298.15 | 1,767.80 |
| July 2028 | 2,253.08 | 1,733.14 |
| August 2028 | 2,322.77 | 1,786.74 |
| September 2028 | 2,404.06 | 1,849.28 |
| October 2028 | 2,466.57 | 1,897.36 |
| November 2028 | 2,528.23 | 1,944.80 |
| December 2028 | 2,591.44 | 1,993.42 |
| When | Maximum Price | Minimum Price |
| January 2029 | 2,643.27 | 2,033.28 |
| February 2029 | 2,711.04 | 2,085.42 |
| March 2029 | 2,816.78 | 2,166.75 |
| April 2029 | 2,761.54 | 2,124.27 |
| May 2029 | 2,681.11 | 2,062.39 |
| June 2029 | 2,801.76 | 2,155.20 |
| July 2029 | 2,746.82 | 2,112.94 |
| August 2029 | 2,831.78 | 2,178.29 |
| September 2029 | 2,930.89 | 2,254.53 |
| October 2029 | 3,007.09 | 2,313.15 |
| November 2029 | 3,082.27 | 2,370.98 |
| December 2029 | 3,159.33 | 2,430.25 |
| When | Maximum Price | Minimum Price |
| January 2030 | 3,222.51 | 2,478.86 |
| February 2030 | 3,305.14 | 2,542.42 |
| March 2030 | 3,434.04 | 2,641.57 |
| April 2030 | 3,366.71 | 2,589.78 |
| May 2030 | 3,268.65 | 2,514.35 |
| June 2030 | 3,415.74 | 2,627.49 |
| July 2030 | 3,348.76 | 2,575.97 |
| August 2030 | 3,452.33 | 2,655.64 |
| September 2030 | 3,573.17 | 2,748.59 |
| October 2030 | 3,666.07 | 2,820.05 |
| November 2030 | 3,757.72 | 2,890.55 |
| December 2030 | 3,851.66 | 2,962.82 |
As we move into January 2030, Zydus Lifesciences is projected to see a maximum price of ₹3,222.51 and a minimum price of ₹2,478.86. Continuing into February, the maximum price is expected to rise to ₹3,305.14, with the minimum also increasing to ₹2,542.42. March may bring further increases, with Zydus Lifesciences anticipated to reach a maximum price of ₹3,434.04 and a minimum price of ₹2,641.57. The trend of growth persists through the year, with December witnessing Zydus Lifesciences at a maximum of ₹3,851.66 and a minimum of ₹2,962.82.
Financial Condition of Zydus Lifescience: Last 5 years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
| Sales + | 14,253 | 14,404 | 15,110 | 17,237 | 19,547 |
| Expenses + | 11,455 | 11,013 | 11,768 | 13,378 | 14,163 |
| Operating Profit | 2,798 | 3,391 | 3,342 | 3,860 | 5,384 |
| OPM % | 20% | 24% | 22% | 22% | 28% |
| Other Income + | -264 | -231 | 2,581 | -422 | 293 |
| Interest | 342 | 159 | 127 | 130 | 81 |
| Depreciation | 696 | 670 | 713 | 723 | 764 |
| Profit before tax | 1,495 | 2,331 | 5,084 | 2,585 | 4,832 |
| Tax % | 21% | 8% | 10% | 23% | 20% |
| Net Profit + | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 |
| EPS in Rs | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 |
| Dividend Payout % | 30% | 17% | 6% | 31% | 8% |
Looking at the financials from March 2020 to March 2024, there’s a consistent growth trajectory evident for the company. Sales have steadily increased from 14,253 in March 2020 to 19,547 in March 2024. Similarly, operating profit has shown a notable uptrend, rising from 2,798 in March 2020 to 5,384 in March 2024, with a peak operating profit margin (OPM) of 28% in March 2024. Despite fluctuations, the company has managed to maintain a healthy profit before tax, reaching a peak of 5,084 in March 2022. Net profit has also seen steady growth, peaking at 4,618 in March 2022, leading to an increase in earnings per share (EPS) over the years. The dividend payout percentage has varied, indicating the company’s strategy in distributing profits to shareholders while ensuring reinvestment for growth. Overall, the financials demonstrate a positive trend of growth and profitability for the company over the years.
FAQS
As of 7th July 2024, the current share price of Zydus Lifesciences is ₹1,162.
Zydus Lifesciences’ share prices ranging from a projected high of ₹1,534.20 to a anticipated low of ₹1,004.68.
The expected maximum price prediction for 2030 is ₹3,851.66.
Some of the factors that may impact Zydus Lifesciences’ share price target include the company’s financial performance, changes in industry regulations, and global economic conditions.
As with any investment, it is important to conduct thorough research and analysis before making a decision. While some analysts predict growth for the company, it is important to consider various factors that may impact the share price target in the coming years.
ALSO READ:
- UNITED SPIRITS LTD SHARE PRICE TARGET 2024-2030
- BOSCH LTD SHARE PRICE TARGET 2024-2030
- SHRIRAM FINANCE LTD SHARE PRICE TARGET 2024-2030
CONCLUSION
Zydus Lifesciences offers an enticing investment opportunity within the pharmaceutical sector. With consistent financial growth, highlighted by strong revenue and prudent expense management, the company has solidified its position in the market. The recent approval of a share buyback program underscores management’s confidence and commitment to enhancing shareholder value. With an innovative product portfolio and strategic initiatives, Zydus Lifesciences is well-positioned for continued success in the evolving healthcare landscape, making it a compelling option for long-term investors.
Disclaimer: I do not hold Zydus Lifescience shares in my portfolio. And this is not a financial advice. We are not registered with SEBI.
What did we learn?
- 1 Zydus Lifesciences Q4: Net Profit Surges Fourfold to Rs 1,182 Crore, Revenue Up 10%
- 2 How to purchase Zydus Lifescience shares?
- 3 Zydus Lifesciences Share Price Target: 2024, 2025 to 2030
- 3.1 Zydus Lifesciences Share Price Target 2024
- 3.2 Zydus Lifesciences Share Price Target 2025
- 3.3 Zydus Lifesciences Share Price Prediction 2026
- 3.4 Zydus Lifesciences Share Price Target 2027
- 3.5 Zydus Lifesciences Share Price Target 2028
- 3.6 Zydus Lifesciences Share Price Prediction 2029
- 3.7 Zydus Lifesciences Share Price Prediction 2030
- 4 Financial Condition of Zydus Lifescience: Last 5 years
- 5 FAQS
- 5.1 What is the current share price of Zydus Lifesciences?
- 5.2 What is the predicted share price target for Zydus Lifesciences by 2025?
- 5.3 What is the predicted share price target for Zydus Lifesciences by 2030?
- 5.4 What are some of the factors that may impact Zydus Lifesciences’ share price target in the coming years?
- 5.5 Is it a good time to buy Zydus Lifesciences shares?
- 6 CONCLUSION
Twitter
Linkedin
